AUGUSTIN, M.; WEGTOWSKA, J.; LEBWOHL, M.; PAUL, C.; PIGUET, V.; SOFEN, H.; BLAUVELT, A.; PETERSON, L.; AL., E. Durability of Response in Patients with Chronic Plaque Psoriasis Treated with Certolizumab Pegol over 48 Weeks: Pooled Results from Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT). SKIN The Journal of Cutaneous Medicine, v. 2, p. S87, 17 Dec. 2018.